Podcasts about aacr

On this edition of Insight, we examine three important issues impacting our communities: justice and accountability, youth empowerment, and the fight against cancer disparities. First, we discuss the growing community movement seeking justice for 19-year-old Wyleek Tinsley, who was fatally shot by Abington Township police officers inside his home on March 6, 2025. Joining us are Wyleek's brother, Jahvonn Brooks and Tyree Wallace, Founder and CEO of Systemic Reformative Change (SRC). They share details about the #JusticeForWyleekTinsley campaign, the family's call for transparency and accountability, ongoing organizing efforts, and broader conversations around police accountability, public trust, and systemic reform. Learn more at www.srcnow.org and follow the campaign using #JusticeForWyleekTinsley. https://www.gofundme.com/f/support-systemic-reformative-change-foundation https://www.instagram.com/justiceforwyleek/  Next, we turn our attention to empowering young women with Cheryl Wadlington, founder of Evoluer House and creator of Holistic Me, a free virtual summer workshop series for girls ages 13 to 18. Running June 22 through August 21, the program offers more than 25 workshops focused on wellness, financial literacy, leadership development, personal safety, college preparation, and career readiness. Cheryl discusses the challenges facing teen girls today and how Holistic Me is helping participants build confidence and prepare for the future. For registration and information, visit www.evoluerhouse.org and follow Evoluer House on social media.  Finally, we speak with Dr. Clayton Yates, John R. Lewis Endowed Professor and Director for Translational Health Disparities and Global Health Equity Research at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine. Dr. Yates discusses cancer disparities, groundbreaking research, and the importance of investing in health equity. The conversation comes as WDAS-FM prepares for the 9th Annual Sista Strut 3K Breast Cancer Walk on Saturday, June 20, 2026, at Stateside Live in Philadelphia. Sista Strut raises awareness about breast cancer in women of color and supports lifesaving research through the American Association for Cancer Research (AACR). Learn more at www.aacr.org.   Join us for informative conversations that inspire action, build awareness, and strengthen our communities.  

Send us Fan MailFor years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn't just finding a better target...it's that cancer may never have been a single-target disease in the first place.Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( https://deck.bio/ ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape.Deck Bio's platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies.Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D. at Stanford University, where he was a Bio-X interdisciplinary fellow, and later worked at Johns Hopkins University on early clinical and translational oncology studies, including work on AR-V7 as a resistance biomarker in prostate cancer and early immune checkpoint combination trials. His background spans both deep immunology and real-world clinical translation in oncology.Dr. Silberstein joins us following Deck Bio's recent preclinical presentation at AACR 2026 in San Diego, where the company shared early data on its multi-pMHC targeting strategy.#DeckBio #JackSilberstein #Immunotherapy #CancerResearch #TCellEngagers #Biotech #AACR2026 #SolidTumors #CancerTherapy #TCellTherapy #PrecisionMedicine #Oncology #TCRTherapy #CancerInnovation #Biotechnology #ImmuneSystem #CellTherapy #CancerBreakthrough #SyntheticBiology #FutureOfMedicineSupport the show

Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1, FBXW7, and PPP2R1A-altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50% at the potential recommended phase 2 dose. These data were presented by Timothy A. Yap, MBBS, PhD, FRCP, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following his presentation, Yap joined CancerNetwork® for a discussion where he highlighted some of the most interesting takeaways from the trial. According to Yap, the disease states evaluated in this trial represent areas of unmet need where no specific standard-of-care options can target these alterations.Notably, based on results from this trial, the FDA granted fast track designation to lunresertib in combination with zedoresertib in patients with genomic-defined platinum-resistant ovarian cancer.2Yap is a medical oncologist and physician-scientist, as well as the Random Horne, Jr. Endowed Professor for Cancer Research and vice president and head of Clinical Development in the Therapeutics Discovery Division at UT MD Anderson Cancer Center.References1.        Yap TA, Aggarwal R, Fontana E, et al. First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations. Presented at the 2026 AACR Annual Meeting; April 17-22, 2026; San Diego, CA. Abstract CT022.2.        Following oral presentation of phase I Data at AACR 2026, Debiopharm announces FDA fast track designation for lunresertib in combination with zedoresertib for genomic-defined platinum-resistant ovarian cancer. News release. Debiopharm. April 20, 2026. Accessed May 4, 2026. https://shorturl.at/n1bWn

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess. Guests: Deborah Doroshow, MD, PhD Associate Professor of Medicine, Hematology/Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai David S. Hong, MD Douglas E. Johnson Endowed Professor Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program] Division of Cancer Medicine Clinical Medical Director, Clinical and Translational Research Center The University of Texas MD Anderson Cancer Center Jonathan Riess, MD Associate Professor of Medicine, UC Davis Comprehensive Cancer Center Director of Thoracic Oncology, University of California, Davis

More than 175 new oncology targets surfaced at this year's American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury's analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates.The analysts also discuss Eli Lilly's latest deal — for a JAK-2 inhibitor from Ajax — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners' new venture fund and the latest in BioCentury's Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company Elevara Medicines. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.View full story: https://www.biocentury.com/article/659298#AACR #OncologyTargets #Immunotherapy #BiotechMA #ADC00:01 - Sponsor Message: IQVIA Biotech02:50 - AACR: New Targets11:08 - AACR: Pan-RAS Inhibitor ADCs15:35 - Biopharma Deals23:53 - Kurma's New Venture Fund27:28 - Emerging Company Profile: ElevaraTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry. At the latest meeting of the American Association for Cancer Research, innovative cancer therapies were in the spotlight. Merck showcased its PD-1xVEGF bispecific antibody for non-small cell lung cancer, combining immune checkpoint inhibition with anti-angiogenic strategies. This novel approach could enhance efficacy and safety compared to existing treatments. Despite these promising developments, Merck remains cautious about disclosing its Phase 3 trial plans, likely due to competitive pressures. The conference also featured industry veterans like Dr. Daniel Chen, who is pioneering "smart" cancer drugs through his startup. These antibody-drug conjugates aim to deliver targeted therapies with precision, minimizing off-target effects—a clear nod towards personalized medicine tailored to the genetic profiles of tumors. Revolution Medicines is making strides in targeting RAS mutations, particularly in pancreatic cancer, with its lead candidate daraxonrasib showing promise in Phase 3 trials. This positions the drug as a potential breakthrough for this challenging cancer type. Their broader pipeline suggests a strategic focus on exploiting RAS pathways, heralding a new wave of targeted cancer therapies. Meanwhile, National Cancer Institute Director Letai reassured attendees about stable research funding amidst political uncertainties, aiming to sustain momentum in cancer research advancements. Regulatory concerns were also a focal point at AACR. Dr. Richard Pazdur expressed anxiety over political influences impacting the U.S. FDA, reflecting broader challenges within regulatory frameworks that could affect drug approval processes and innovation timelines. On an international note, Zai Lab's global expansion ambitions were examined. Transitioning from licensing deals to independent biopharmaceutical development illustrates China's growing influence in biotech, though scaling operations across diverse regulatory environments presents significant challenges. In another significant development, Regeneron secured FDA approval for a pioneering gene therapy, underscoring rapid advances toward personalized therapies for genetic disorders. This marks a new era in genetic medicine and highlights the transformative potential of gene therapy. Meanwhile, Pfizer's strategic post-COVID-19 restructuring has resulted in further layoffs in Ireland, reflecting broader industry trends towards financial recalibration. Such moves underscore the ongoing adjustments companies face as they adapt to post-pandemic market dynamics. Pfizer's strategic portfolio management reflects a trend towards focusing resources on promising late-stage assets while deprioritizing earlier-stage projects that don't align with evolving goals. Roche's oral selective estrogen receptor degrader giredestrant remains a focal point despite clinical data concerns. Positioned as a potential major product in oncology, it illustrates the complexities involved in commercializing promising therapies amid data uncertainties. Sanofi continues to drive growth with Dupixent while preparing legal defenses to extend U.S. exclusivity beyond 2031—a strategic effort to protect revenue streams against generic competition. Conversely, AbbVie's attempt to introduce a Botox successor faced setbacks due to manufacturing-related issues flagged by the FDA, highlighting the complexities of meeting stringent regulatory standards. Avalyn Pharma's $182 million IPO signifies strong investor confidence in late-stage respiratory drug candidates, emphasizing efforts to innovate in chronic disease management. Regulatory dynamics are evolving too, with initiatives aimed at exSupport the show

Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year's American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury's analysts to discuss what AACR revealed about modalities gaining traction, plus shares his perspective on de-risking clinical development and eliminating the “white space” that delays biotechs' timelines in the clinic. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.View full story: https://www.biocentury.com/article/659235 #AACR #BispecificAntibodies #ADC #OncologyData #ClinicalDevelopment 00:01 - Sponsor Message: IQVIA Biotech01:43 – AACR Early Signals05:17 – Antibody Innovation09:22 – Dual Payload ADCs13:48 – De-Risking Drug Development19:16 – Looking Ahead to ASCOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

21. april 2026 I denne episoden er Jónas Einarsson tilbake i studio for en bred nyhetsgjennomgang fra kreft- og biotekfeltet. Vi starter med å fortelle om noen endringer i podkasten: fremover vil Radium dekke et bredere spekter av kreftrelaterte temaer – ikke bare porteføljeselskaper og børsnotert biotek, men også forskning, klinikk, politikk, teknologi og diagnostikk. Deretter rapporterer Jónas fra Zellunas kapitalmarkedsdag 14. april. Videre går vi gjennom en rekke nyheter: Nykode Therapeutics har fått godkjenning til å starte fase 2-studien Abilit-T i syv europeiske land, og presenterer nye lovende data på kreftkonferansen AACR denne uken. Photocures kinesiske partner Asieris melder om sterk vekst og et vendepunkt i 2026 – men et betalingsstridsspørsmål knyttet til Cevira-godkjenningen skaper hodebry. Circio har hentet 250 millioner kroner i en kraftig overtegnet emisjon. ARTBIO har satt fase 1-studien sin på pause etter produksjonsutfordringer. Thor Medical melder at AlphaOne-anlegget på Herøya er mekanisk ferdigstilt – på tid og innenfor budsjett. Og Revolution Medicines har vist oppsiktsvekkende fase 3-resultater for en ny behandling mot bukspyttkjertelkreft. Til slutt: sett av mandag 10. august til kreftdagen under Arendalsuka. Neste uke: historien om John Ugelstad, Dynal-eventyret og grunnlaget for Thermo Fishers globale suksess.

A 2026 prospective cohort study published in Cancer Epidemiology, Biomarkers & Prevention investigated the impact of ultra-processed foods (UPFs) on the long-term survival of cancer patients. Tracking 802 cancer survivors over a median of 14.6 years within the Moli-sani Study, researchers discovered a stark correlation between the consumption of UPFs and mortality risk.The data revealed that individuals consuming the highest amount of ultra-processed foods (measured by weight ratio) experienced a 48% higher rate of all-cause mortality and a 57% higher rate of cancer-specific mortality compared to those in the lowest consumption tier. Crucially, this association persisted even after adjusting for overall diet quality, indicating that the industrial processing itself—rather than just a poor nutrient profile—plays an independent and harmful role in long-term health. The study identified that increased systemic inflammation and an elevated resting heart rate accounted for over 37% of this link, demonstrating how artificial additives and industrial processing disrupt metabolic function.Disclaimers• This information is for educational purposes only and is not medical advice.• The findings are based on an observational study, meaning causality cannot be definitively inferred.• Dietary intakes were self-reported, which can be susceptible to misreporting or changes over the lengthy follow-up period.• Nutritional interventions and major dietary changes should always be managed by a qualified healthcare professional or oncology nutritionist.#CancerSurvival #UltraProcessedFoods #UPF #NutritionScience #OncologyNutrition #HealthyEating #DietAndCancer #ScienceUpdate #Alchepharma #Inflammation #FoodProcessing ultra-processed foods cancer survivors 2026, NOVA classification UPF mortality, diet for cancer recovery, Moli-sani study cancer research, inflammation UPF heart rate, 48% higher mortality processed food, AACR cancer epidemiology diet, artificial additives cancer risk, whole foods oncology nutrition, effects of food processing on health, ultra-processed food all cause mortality.

What happens when lived experience, science, and nonprofit leadership collide? In this episode, I sit down with Dr. Eugene Manley, Jr. to discuss health equity, cancer care gaps, and what it truly takes to design programs that serve communities that have been overlooked for far too long. We explore how focus, intentionality, and listening to the people most impacted can turn complex equity challenges into meaningful, measurable action. Episode Highlights 02:32 Dr. Manley's Personal Journey and Inspiration 04:01 Challenges in the Hospital System 05:24 Launching the STEM and Cancer Equity Foundation 06:18 Addressing Health Disparities and Patient Advocacy 10:11 The Importance of Early Exposure to STEM 11:01 Navigating Academia and Nonprofit Work 11:57 The Lung Cancer Health Equity Summit 16:03 Fiscal Sponsorship for Nonprofits 19:46 Defining and Addressing Health Equity 22:03 Challenges in Lung Cancer Clinical Trials My guest for this episode is Dr. Eugene Manley, Jr., PhD, MS. Dr. Eugene Manley, Jr., PhD, MS, is a biomedical scientist-turned-social impact leader and the Founder & CEO of the STEMM & Cancer Health Equity (SCHEQ) Foundation. He brings 20+ years across engineering, molecular and cell biology, nonprofit strategy, and workforce development, with prior leadership at leading cancer organizations. He had worked in development at the AACR, grant system administration at LCRF, and directed national STEM and workforce initiatives and health equity initiatives at LUNGevity Foundation.   Through SCHEQ, he advances STEMM workforce diversity and patient-centered solutions across the cancer care continuum, producing health-literacy resources, convening cross-sector stakeholders, and leading the Lung Cancer Interventions Summit to drive practical, equity-focused outcomes for underserved communities. He serves on local, national, and international advisory boards advocating for Medicaid, rural, and historically marginalized patients. Dr. Manley serves on the Stony Brook Cancer Community Advisory Council, PCORI advisory panels focused on healthcare delivery and comparative clinical effectiveness, and has co-authored a perspective work with the American Cancer Society's National Lung Cancer Roundtable on compassion and stigma in lung cancer care. His lived experience, research background, outreach, and policy engagement inform a pragmatic approach to closing gaps in screening, biomarker testing, trial access, and survivorship. Connect with Dr. Eugene: https://www.linkedin.com/in/eugenemanleyjrphd https://www.linkedin.com/company/stemmcheq https://www.facebook.com/stemmcheq https://www.instagram.com/stemmcheq https://www.instagram.com/manleyeugene Sponsored Resource Join the Inspired Nonprofit Leadership Newsletter for weekly tips and inspiration for leading your nonprofit! Access it here >> Be sure to subscribe to Inspired Nonprofit Leadership so that you don't miss a single episode, and while you're at it, won't you take a moment to write a short review and rate our show? It would be greatly appreciated! Let us know the topics or questions you would like to hear about in a future episode. You can do that and follow us on LinkedIn.

Started in Windham, NH, Project Blackout is a 501(c)(3) nonprofit organization on a mission to turn out the lights on pediatric cancer. According to the AACR, the Northeast has the highest pediatric cancer rates in the United States. Dedicated to uniting local towns and schools to help children diagnosed with cancer, Project Blackout aims to educate communities, raise funds for research, and support those affected by pediatric cancer. In this episode, I had the pleasure of speaking with Erica DiNitto, Board President.For more information about Project Blackout, please visit https://www.projectblackoutusa.org/ or https://www.facebook.com/projectblackoutcancer/For more on the Dose of Good Podcast, visithttps://www.facebook.com/profile.php?id=61552349588905https://www.instagram.com/dose_of_good_podcast/https://www.youtube.com/@DoseOfGoodPodcastYou can also email doseofgoodpodcast@gmail.com

Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology to Breakthrough Therapies, September 25-28 in Boston.Dr. Church is currently a Molecular and Pediatric Pathologist at Boston Children's Hospital, where she is a founder and associate medical director of the Laboratory for Molecular Pediatric Pathology (LaMPP). She is an Assistant Professor of Pathology at Harvard Medical School, the Program Director for the Harvard Molecular Genetic Pathology Fellowship, and the incoming Chair of Clinical Practice for the Association for Molecular Pathology. Her clinical and research work focuses on bringing molecular testing to the clinical care of children with cancer. Through institutional projects (the Profile study, GAIN consortium study), she has profiled thousands of children's tumors and has used these results to make real-time impacts on their diagnoses and treatments. She is involved in national initiatives to improve the quality and access to molecular testing for children with cancer, including the NCI-funded Count Me In Study (Dana Farber, Broad Institute), the National Comprehensive Cancer Network, the National Institutes of Health, and the Children's Oncology Group.

We're joined by Dr. Heather K. Beasley, a leading cancer researcher and MAGEC Fellow at Vanderbilt University Medical Center. As Chair of the AACR Associate Member Council, Dr. Beasley is advancing research on cancer disparities, particularly in underserved communities. • AACR – www.aacr.org

Have you ever wondered why the 80/20 rule works in almost every aspect of life, from business to personal connections, and how you can use it to optimize your success? The Pareto Principle, or 80/20 rule, has been around for decades, but do you really understand how deeply it impacts your business? In this episode, we explore not just the basics of 80/20, but how digging deeper into this principle can radically shift your approach to everything from customers to employees, and even your own personal life. Learn how applying 80/20 can uncover your business's true power and profit centers. Discover how to maximize talent and resources by focusing on the most productive elements of your team and customers. Understand why focusing on fewer, better relationships can transform your personal and professional life. Tune in now to discover how embracing 80/20 could be the key to unlocking exponential growth and serenity in your business. Check out: 4:30 – Discover how the 80/20 rule impacts customer relationships and why focusing on your most profitable clients can save time and boost profits. 19:45 – Learn about the “80/20 inside the 80/20” concept and how breaking it down further can reveal hidden opportunities in your business. 35:10 – Gain insights into how the 80/20 rule applies to talent management and why doubling down on strengths, rather than weaknesses, leads to explosive growth. About Our Guest Perry Marshall is one of the most expensive business strategists in the world. He is endorsed in FORBES and Inc. Magazine and has worked with clients such as FanDuel, InfusionSoft, and LoanBuilder. He founded the $10 million Evolution 2.0 Prize, with judges from Harvard, Oxford and MIT. Launched at the Royal Society in London, it's the world's largest science research award. He is co-founder of the AACR's Cancer & Evolution Working Group. NASA's Jet Propulsion Labs uses his 80/20 Curve as a productivity tool. His reinvention of the Pareto Principle was published in Harvard Business Review.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkWelcome to Episode 6 of The Oncology Journal Club podcast. This is where we take a famously different approach to oncology research.Has non-operative management finally found its place in treating certain cancers? This episode unpacks compelling new data that might challenge the surgeon's traditional role for some patients with mismatch repair deficient tumours. While rectal cancer patients show remarkable complete response rates to immunotherapy, the story gets more complex across different cancer types – raising fascinating questions about tumour biology, patient selection and the future of organ preservation.We explore the delicate art of discussing immunotherapy outcomes with patients, navigating that narrow path between hope and realism. When treatments occasionally produce dramatic responses but more commonly offer limited benefits, how do oncologists communicate effectively without creating unrealistic expectations? Our hosts share practical strategies for these challenging conversations, emphasising that truly patient-centred care requires ongoing dialogue about prognosis.The oncology research world is evolving too, with updated CONSORT and SPIRIT guidelines transforming how clinical trials are designed and reported. These frameworks now mandate greater transparency, clearer safety reporting and increased patient involvement in study design – potentially leading to more trustworthy and applicable research outcomes.Plus, we examine an intriguing Chinese trial showing remarkable survival benefits from low-dose continuous capecitabine combined with aromatase inhibitors for metastatic breast cancer – a potential game-changer for resource-limited settings.From this year's AACR meeting, we highlight what might be the first change in standard of care for locally advanced head and neck cancer in two decades, along with promising targeted therapies for specific molecular subtypes of lung cancer. Join our expert hosts Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson as they navigate these developments with their trademark blend of critical analysis, clinical wisdom and humour. Subscribe to The Oncology Newsletter to stay informed about the evolving landscape of oncology care and research.For links to the abstracts and bios of our hosts, head to the show notes on oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

睽違半年Happy Hour總算更新啦！這次若晴跟Angel來聊聊最近剛從研討會回來的一些見聞和心得，非常適合搭配上一集新手村005一起收聽！當然我們也不忘Happy Hour的慣例，跟大家分享了一則近期非常振奮人心的客製化基因療法突破的新聞。等待Happy Hour已久的聽眾趕緊收聽吧！ 節目內容： 跟大家更新一下近況 客製化基因療法大突破 芝加哥三腳貓4/6小聚 AACR開幕式小花絮 跟同事學了poster session的搜集資訊的招數 小廢物拿好拿滿還有免費專業大頭照 NIH fellowship小會議見聞 會議結識新朋友的喜悅 -- Hosting provided by SoundOn

“The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca. In this episode, Galbraith and David Fredrickson, EVP of Oncology Business Unit, join Bloomberg Intelligence analyst Sam Fazeli fresh from ASCO to discuss how AstraZeneca is navigating an increasingly complex oncology landscape. From a legacy in small molecules to a bold push into areas ranging from cell therapy to antibody-drug conjugates, they explain how the company aims to sustain growth and relevance. The discussion also covers new trial designs, biomarker-driven strategies, and why innovation, not exclusivity, is the true metric of success.See omnystudio.com/listener for privacy information.

June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with Keith Flaherty, MD, FAACR, professor of Medicine of Harvard Medical School and president-elect of AACR. They discuss Flaherty's prolific career; how his background led him to pursue a career in medicine; how public and private sectors are coming together in oncology around collaborations; reflections on targeted therapies and technologies; optimism around how AI will impact society and the future of medicine positively; and how we need to detect and treat disease early. Links from this episode:  PEGS Boston Conference & Expo Engineering Bispecific Antibodies Synthetic Design Lab Harvard Medical School AACR 

I sit down with Marina Udier, CEO of Nouscom, a Swiss company working on the Lynch Syndrome vaccine.  Nous209 is designed to intercept tumors in Lynch Syndrome cancers.  The 209 comes from the frameshifts of neoantigens, whether sporadic or hereditary.  Idea is to educate the T-cells before cancers start forming.  The data at AACR presented was very promising.  They are also running a study on metastatic colorectal cancer patients, mostly without Lynch Syndrome, but MSI high.  So how many people are tested positive for Lynch Syndrome each year?  Next steps includes additional investigators and patients for a much bigger trial, at a time to be determined, and of course funding is always a priority.  Suffice it so say, interest is high is seeing this come to late stage development.    

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

On this week's episode, Eric Schmidt and Sam Fazeli are joined by special guests Adam Feuerstein and Peter Kolchinsky to discuss the upward movement of the biotech market along with strong drug launches, deals, and net-positive Q1 earnings, all signaling things may be improving. Next, the group notes the FDA is unlikely to undergo significant reorganization and while this stability is reassuring, complacency should be avoided as headwinds persist. Despite the turmoil, the pharmaceutical industry remains resilient, as people prioritize their health and the need for medicine. The conversation shifts back to the new FDA leadership, highlighting Makary and RFK Jr.'s relationship, anti-vaccine rhetoric and the impacts this may have on vaccine trials. The group notes that at conversations at AACR suggest that large pharma is not worried about the FDA changes, while smaller companies have concerns. BridgeBio's successful launch of Attruby was also discussed, highlighted as a positive trend for the industry. The conversation shifts back to vaccine uncertainty and the future of mRNA given the skepticism from healthcare professionals, illustrated by Moderna's potential delays fortheir flu vaccine combo. The episode ends with Adam's optimistic take on biotech's recent turn toward stabilization. *This episode aired on May 2, 2025.

Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on preclinical research supporting different degraders of SMARCA2 at this year's American Association for Cancer Research (AACR) annual meeting.They also discuss takeaways from Editor in Chief Simone Fishburn's conversation with David Baker, the Nobel-prizewinning pioneer in protein design, and Steve Usdin reports that pharmaceutical industry executives are in a state of alarm over President Trump's push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act's “pill penalty” and FDA Commissioner Marty Makary's decision to reject proposals to reorganize the agency. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655851#biotech #biopharma #pharma #LifeScience #RandD #DrugDevelopment #AACR #SMARCA200:01 - Sponsor Message: Jeito Capital03:01 - AACR Spotlight11:21 - David Baker Protein Design19:12 - Trump's Drug Pricing PlanTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Two companies, Beam Therapeutics and Verve Therapeutics, have developed lead candidates using a safer alternative to conventional CRISPR called base editing. Clinical results have been promising. FDA insiders are calling on FDA Commissioner Marty Makary to fight against agency politicization. The Trump administration, including HHS Secretary Robert F. Kennedy Jr., is accused of distorting and denying scientific truths and potentially censoring information.FDA action alerts include expansion bids for drugs by GSK and Merck. A new AI-powered solution called Generative AIPTP helps life sciences firms streamline clinical workflows. The FDA is rehiring travel staff as lapses begin to show.RFK Jr. is driving a wedge into vaccine conversations. WHO may add obesity drugs for adults to the essential medicines list. Various companies like Merck, GSK, and Roche present key data at AACR 2025.HHS will require placebo-controlled trials for all new vaccines in a radical departure from past practices. Tariffs dominate Q1 earnings, AACR excites the cancer space, CEO pay gaps are discussed, and more news and events are highlighted.

AACR 2025 Highlights by IASLC

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis recently acquired Regulus for $1.7 billion, signaling a trend of increased M&A activity in the pharmaceutical industry. Many companies have hinted at upcoming deals during recent earnings calls, which is seen as a positive sign for the biopharma ecosystem amidst challenges like tariffs and potential drug pricing pressures. GSK remains optimistic about M&A opportunities despite the threat of tariffs, with CEO Emma Walmsley emphasizing a cautious and disciplined approach to dealmaking. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and scalability for research needs. The AACR 2025 conference featured promising data from Marengo and Briacell, while Pfizer CEO Albert Bourla has been lobbying against pharmaceutical industry tariffs proposed by President Trump. Overall, the industry is seeing a mix of challenges and opportunities, with companies navigating trade tensions and economic uncertainties while also pursuing strategic growth through acquisitions and innovative research initiatives.Pharmaceutical companies are navigating political uncertainties, particularly in relation to tariffs and dealmaking with China. Major companies are investing billions in US manufacturing to avoid tariffs threatened by President Trump. Despite lobbying efforts, Trump has expressed national security concerns regarding the pharmaceutical industry. CEO-to-employee pay gaps in the industry remain significant. Novartis, GSK, and AstraZeneca are facing challenges and making strategic shifts in response to political and market conditions. Tariff uncertainty is impacting Q1 earnings, with companies like Merck taking significant financial hits. Despite these challenges, the industry remains active with mergers and acquisitions. Upcoming events and job opportunities in the biopharma sector are highlighted.

Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting this week. On Pfizer's call, CEO Albert Bourla called the Trump administration's national security concerns “legitimate,” but objected to the proposed tariffs in general. Meanwhile, Novartis CEO Vas Narasimhan brushed off the tariff risk but expressed concern over President Donald Trump's desire to bring back the ‘Most Favored Nations' rule.  Meanwhile, cancer conference season is in full swing, with the American Association for Cancer Research's annual event continuing in Chicago. Merck, GSK, Boehringer Ingelheim, Roche and others have presented highly anticipated data from some of their cornerstone cancer drugs and other candidates.  Turning to the latest news out of the FDA, newly minted Commissioner Marty Makary gave his first two big press interviews last week, making statements that both jibed with and contradicted recent reporting. And in the midst of the ongoing Novavax vaccine saga, many have raised concerns that the FDA could become politicized under the watch of HHS Secretary RFK Jr.  Finally, check out this week's BioPharm Executive stories, including a deep dive into the trend toward mining innovative therapies from China and BioSpace's annual report on pharma CEO-to-employee pay ratios. 

Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate, according to BioCentury's Washington editor Steve Usdin. On the latest BioCentury This Week podcast, BioCentury's editors discuss how the turmoil at FDA could affect a sector already grappling with the uncertainty brought by the Trump administration's trade war.The editors also explore the growing pipeline of VEGF-targeted bispecifics in a preview of upcoming presentations at annual meeting for the American Association for Cancer Research (AACR). And they discuss how companies may once again need to lean on their bear market survival toolkit, as part of BioCentury's 2Q25 Financial Markets Preview. This episode of BioCentury This Week was sponsored by RemeGen Co.View full story: https://www.biocentury.com/article/65556600:01 - Sponsor Message: RemeGen Co. 01:19 - FDA and Tariffs Turmoil16:54 - AACR Preview20:44 - Bear Market ToolkitTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this special episode, I sit down with Ricki Fairley of TOUCH, The Black Breast Cancer Alliance and Hayley Dinerman of the Triple Negative Breast Cancer Foundation to discuss the latest advancements in TNBC research, including key takeaways from SABCS 2024, new immunotherapy and targeted therapies, and the impact of the AACR research grant. We also explore efforts to address racial disparities, upcoming awareness initiatives, and how you can get involved. Don't miss this insightful conversation about the future of TNBC treatment and advocacy. Thank you to Merck, Daiichi-Sankyo, Gilead, Pfizer, and Lilly for making this episode possible!  

JCO PO author Dr. David R. Gandara at UC Davis Comprehensive Cancer Center, shares insights into his JCO PO article, “Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer,” one of the Top Articles of 2024. Host Dr. Rafeh Naqash and Dr. Gandara discuss how the PROphet® blood test supports first-line immunotherapy treatment decisions for metastatic NSCLC patients. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today, we are absolutely thrilled to be joined by Dr. David R. Gandara, Professor of Medicine Emeritus, Co-Director of the Center for Experimental Therapeutics and Cancer and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center and also the senior author of the JCO Precision Oncology article entitled “Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer.” This was one of the top performing articles of 2024, which is one of the reasons why we wanted to bring it in for a podcast discussion. At the time of this recording, our guest's disclosures will be linked in the transcript.  David, it is an absolute pleasure to have you today. For somebody like you who's led the field of lung cancer over the years, I'm really excited that you are going to be talking to us about this very interesting article, especially given that I think you're one of the big proponents of liquid biopsies and plasma-based testing. So, for the sake of our listeners - which comprises of academic oncologists, community oncologists, trainees - could you tell us where the biomarker landscape for non-small cell lung cancer is currently, and then we can try to take a deeper dive into this article. Dr. David Gandar: Okay. Well, thank you, Rafeh. It's a pleasure to be with you here today. And I think the current landscape for biomarkers for immunotherapy in non-small cell lung cancer is a mess. There's no better way to describe it. That makes this paper describing a new plasma proteomic assay even more important. So I'll just give you a perspective. There are 14 trials, phase three trials, that were done in first line non-small cell lung cancer advanced stage of immunotherapy versus chemotherapy and some other aspects, although they vary tremendously. Some of them were checkpoint monotherapy, some combined with chemotherapy, some combined with CTLA-4 inhibitors and so forth. 12 out of the 14 were positive, 12 got FDA approval. So there are 12 different options that an oncologist could use. Some of them were squamous cell only, some non-squamous, some used PD-L1 as a biomarker driven part of the study. Some used TMB, tumor mutational burden, some were agnostic. So when you put all of this together, an oncologist can pick and choose among all these various regimens. And by and large, it's PD-L1 that is the therapeutic decision maker.  ASCO actually, I think, has done the very best job of making a guideline, and it's, as you well know, called a living guideline, it's dynamic. And it is much easier to interpret, for me and I think for oncologists, than some of the other guidelines. It's got a green light and a red light, it may be kind of orange. And so the green light means this is a strong recommendation by the guideline committee. The orange means it's weak. For this purpose, non-small cell lung cancer, advanced stage, only a very few of the recommendations were green. It's mainly monotherapy and patients with cancers with a PD-L1 over 50%. In our surveys, at our meetings, less than 50% of oncologists in the United States are following these guidelines. Why? Because they don't trust the biomarker. And TMB has the same sort of limitations. They're not bad biomarkers, they're incomplete. They're only looking at a part of the story. So that means we need a new biomarker. And this is one that, I think, the data are quite impressive and we'll discuss it more. Dr. Rafeh Naqash: Absolutely. Like you said, abundance of many therapy options, but not necessarily everything works the same in different subsets of PD-L1 positivity or different subsets of patients with different levels of tumor burden. And like you said, again, difficulty in trying to identify the right biomarker. And that's a nice segue to this PROphet test that you guys ran. So can you tell us a little bit about the plasma proteomic assay? Because to the best of my knowledge, there's not a lot of validated plasma proteomic assays. A lot has been done on the tumor tissue side as far as biomarkers are concerned, but not much on the blood side, except for maybe ctDNA MRD testing. So what was the background for trying to develop a plasma-based proteomic test? And then how did this idea of testing it in the lung cancer setting come into play? And then we can go into the patient population specifics, the cohort that you guys have. Dr. David Gandara: Okay. Well, of course there's a company behind this assay, it's called OncoHost, and I'm a consultant for them. And they came to me two years ago and they said, “We have something different from anyone else.” And they explained the science to me, as well as some other lung cancer experts here in the United States. I'm not a proteomic expert, of course, but they developed an AI machine learning platform to assess plasma proteins in normal people and in people with cancer, and specifically then in people with non-small cell lung cancer. They identified over 7,000 proteins that had cancer implications for therapy, for resistance, for prognosis, etc., and they categorized them based on the literature, TCGA data, etc., and used this machine learning process to figure out which proteins might be most specific for non-small cell lung cancer. And that's where they started. And so out of that 7,000 proteins, where they've identified which ones are angiogenic, which ones are involved with EMT or cell cycle or whatever it might be, they distilled it down to 388 proteins which they thought were worth testing in non-small cell lung cancer. And that's when I became involved.  They had a retrospective cohort of patients that had been treated with various immunotherapies. They looked at the analytic validation first, then applied it to this cohort. It looked good. Then they had a very large cohort, which they split, as you usually do with an assay, into a test set and then a validation set. For the test set, they wanted something more than a response. They wanted some indicator of long term benefit because that's where immunotherapy differentiates itself from chemotherapy and even targeted therapy. And so they picked PFS at 12 months. And I became involved at that point and it looked really good. I mean, if you look at the figures in the manuscript, the AUC is superb about their prediction and then what actually happened in the patient. And then in this paper, we applied it to a validation set of over 500 patients in a prospective trial, not randomized, it's called an observational trial. The investigator got to pick what they thought was the best therapy for that patient. And then in a blinded fashion, the proteomic assay experts did the analysis and applied it to the group.  And so what that means is some of the patients got chemotherapy alone, some got checkpoint immunotherapy monotherapy, some got in combination with chemotherapy. None of the patients in this study got a CTLA-4 inhibitor. That work is ongoing now. But what the study showed was that this assay can be used together with PD-L1 as what I would call a composite biomarker. You take the two together and it informs the oncologist about the meaning of that PD-L1. I'll give you an example. If that patient has a PD-L1 over 50% in their cancer and yet the PROphet test is negative, meaning less than 5 - it's a 0 to 10 scale - that patient for survival is better served by getting chemotherapy and immunotherapy. However, if the PROphet test is positive and the PD-L1 is over 50%, then the survival curves really look equivalent. As I said earlier, even in that group of patients, a lot of oncologists are reluctant to give them monotherapy. So if you have a test and the same sort of example is true for PD-L1 0, that you can differentiate. So this can really help inform the oncologist about what direction to go. And of course then you use your clinical judgment, you look at what you think of as the aggressiveness of the tumor or their liver metastases, etc. So again, that's how this test is being used for non-small cell lung cancer. And maybe I'll stop there and then I'll come back and add some other points. Dr. Rafeh Naqash: I definitely like your analogy of this therapy de-escalation strategy. Like you mentioned for PD-L1 high where the PROphet test is negative, then perhaps you could just go with immunotherapy alone. In fact, interestingly enough, I was invited to a talk at SITC a couple of weeks back and this exact figure that you're referring to was one of the figures in my slide deck. And it happened by chance that I realized that we were doing a podcast on the same paper today.  So I guess from a provocative question standpoint, when you look at the PD-L1 high cohort in the subset where you didn't see a survival difference for chemo plus immunotherapy versus immunotherapy alone, do you think any element of that could have been influenced by the degree of PD-L1 positivity above 50%? Meaning could there have been a cohort that is, let's say PD-L1 75 and above, and that kind of skews the data because I know you've published on this yourself also where the higher the PD-L1 above 50%, like 90% PD-L1 positivity survival curves are much better than 50% to 89%. So could that have somehow played a role? Dr. David Gandara: The first thing to say is that PD-L1 and the PROphet score, there's very little overlap. I know that sounds surprising, but it's also true for tumor mutational burden. There's very little overlap. They're measuring different things. The PD-L1 is measuring a specific regulatory protein that is applicable to some patients, but not all. That's why even in almost all of the studies, people with PD-L1 0 could still have some survival benefit. But in this case they're independent. And not in this paper, but in other work done by this group, the PROphet group, they've shown that the PROphet score does not seem to correlate with super high PD-L1. So it's not like the cemiplimab data where if you have a PD-L1 of greater than 90%, then of course the patient does spectacularly with monotherapy. The other thing that's important here is they had a group of around a little less than 100 patients that got chemotherapy alone. The PROphet score is agnostic to chemotherapy. And so that means that you're not just looking at some prognostic factor. It's actually clinical utility on a predictive basis. Dr. Rafeh Naqash: I think those are very important points. I was on a podcast a couple of days back. I think there's a theme these days we're trying to do for JCO Precision Oncology, we're trying to do a few biomarker based podcasts, and the most recent one that we did was using a tissue transcriptome with ctDNA MRD and you mentioned the composite of the PD-L1 and the PROphet test and they use a composite of the tissue transcriptome. I believe they called it the VIGex test as well as MRD ctDNA. And when your ctDNA was negative at, I believe, the three month mark, those individuals had the highest inflamed VIGex test or highest infiltration of T cells, STING pathway, etc. So are there any thoughts of trying to add or correlate tissue based biomarkers or ctDNA based correlations as a further validation in this research with the company? Dr. David Gandara: Right. So there are many things that are being looked at, various composites looking at the commutations that might affect the efficacy of immunotherapy and how they correlate with profit positivity or negativity. And I'll just give the examples of STK11 and KEAP1. As you know, there's some controversy about whether these are for immunotherapy, whether they're more prognostic or predictive. I'm one of the co-authors among many in the recently published Nature paper by Dr. Skoulidis and the group at MD Anderson which report that for KEAP1 positive especially, but also SDK11 mutated getting immunotherapy, that that's where the CTLA-4 inhibitors actually play the greatest role. So realizing that this is still controversial, there are preliminary data, not published yet, that'll be presented at an upcoming meeting, looking at many of these other aspects, P53, SCK11, KEAP1, other aspects, TMB, that's actually already published, I think in one of their papers. So yes, there's lots of opportunities.  The other cool thing is that this isn't a test, it's a platform. And so that means that the OncoHost scientists have already said, “What if we look at this test, the assay in a group of patients with small cell lung cancer?” And so I just presented this as a poster at the world conference in San Diego. And it turns out if you look at the biology of small cell, where neither PD-L1 nor TMB seem to be very important, if you look at the biology of small cell and you form an assay, it only shares 44 proteins out of the 388 with non-small cell. It's a different biology. And when we applied that to a group of patients with small cell lung cancer, again it had really pretty impressive results, although still a fairly small number of patients. So we have a big phase three study that we're doing with a pharmaceutical company developing immunotherapy where we are prospectively placing the PROphet test in a small cell trial.  The platform can also be altered for other cancer types. And at AACR, Dr. Jarushka Naidoo presented really impressive data that you can modify the proteins and you can predict immunotherapy side effects. So this is not like a company that says, “We have one test that's great for everything.” You know how some companies say, “Our test, you can use it for everything.” This company is saying we can alter the protein structures using AI machine learning assisted process to do it and we can have a very informed assay in different tumor types and different situations. So to me, it's really exciting. Dr. Rafeh Naqash: Definitely to me, I think, combining the AI machine learning aspect with the possibility of finding or trying to find a composite biomarker using less invasive approaches such as plasma or blood, definitely checks a lot of boxes. And as you mentioned, trying to get it to prospective trials as an integral biomarker perhaps would be likely the next step. And hopefully we see some interesting, exciting results where we can try to match or stratify patients into optimal combination therapies based on this test.  So now to the next aspect of this discussion, David, which I'm really excited about. You've been a leader and a mentor to many. You've led ISLC and several other corporate group organizations, et cetera. Can you tell us, for the sake of all the listeners, junior investigators, trainees, what being a mentor has meant for you? How your career has started many years back and how it's evolved? And what are some of the things that you want to tell people for a successful and a more exciting career as you've led over the years? Dr. David Gandara: Well, thank you for the question. Mentoring is a very important part of my own career. I didn't have an institutional mentor when I was a junior investigator, but I had a lot of senior collaborators, very famous people that kind of took me under their wing and guided me. And I thought when I basically establish myself, I want to give back by being a mentor to other people. And you wouldn't believe the number of people that I'm even mentoring today. And some of them are not medical oncologists, they're surgeons, they're radiation oncologists, they're basic scientists. Because you don't have to be an expert in that person's field to be a mentor. It helps, but in other words, you can guide somebody in what are the decision making processes in your career. When is it time to move from this institution onward because you can't grow in the institution you're in, either because it's too big or it's too small? So I established a leadership academy in the Southwest Oncology Group, SWOG. I've led many mentoring courses, for instance, for ISLC, now for International Society Liquid Biopsy, where I'm the executive committee liaison for what's called The Young Committee. So ISLB Society, totally devoted to liquid biopsy, six years old now, we have a Young Committee that has a budget. They develop projects, they publish articles on their own, they do podcasts. So what I'm saying is those are all things that I think opens up opportunities. They're not waiting behind senior people, they are leading themselves.  We just, at our International Lung Cancer Congress, reestablished a fellows program where a group of fellows are invited to that Huntington beach meeting. It's now in its 25th year and we spend a day and a half with them, mentoring them on career building. I'll just give you my first, I have the “Letterman Top 10”. So my first recommendation is if all you have is lemons, make lemonade. And what I'm meaning is find what you can do at your institution if you're a junior person, what you can claim to be your own and make the very best of it. But then as you get further along in my recommendations, one of them is learn when to say ‘no'. Because as a junior investigator the biggest threat to your career is saying ‘yes' to everybody and then you become overwhelmed and you can't concentrate. So I'll stop there. But anyway, yes, mentoring is a big part of my life. Dr. Rafeh Naqash: Well, thank you, David. This is definitely something that I'm going to try to apply to my career as well. And this has been an absolute pleasure, especially with all the insights that you provided, not just on the scientific side but also on the personal career side and the mentorship side. And hopefully we'll see more of this work that you and other investigators have led and collaborated on. perhaps more interesting plasma based biomarkers. And hopefully some of that work will find its home in JCO Precision Oncology. Thank you again for joining us today. Dr. David Gandara: My pleasure. Dr. Rafeh Naqash: And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service organization, activity or therapy should not be construed as an ASCO endorsement.   Dr. David Gandara Disclosures: Consulting or Advisory Role Company: Henlius USA, Foundation Medicine, Janssen Pharma, Merck & Co, Mirati Therapeutics, Regeneron, AstraZeneca, Guardant Health, Genentech, Exact Sciences  Research Funding Company: Amgen, Genentech, Astex Pharma  

Dr. Vivek Subbiah returns for another edition of Vivek's Takes, sharing his insights on key updates from ESMO Congress 2024, including breakthroughs in neuroendocrine tumors, gastric cancer, and non-small cell lung cancer. He also delves into the highlights of his AACR debate on integrating early cancer detection with AI, arguing for the transformative potential of humans with AI versus the readiness of AI today. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Perry Marshall is a world-renowned business strategist, celebrated for his expertise in applying the 80/20 Principle to transform businesses from seven-figure revenue to eight figures. Endorsed by FORBES and INC Magazine, Perry is one of the most expensive and influential consultants. He has authored ten books, including the acclaimed Ultimate Guide to Google Ads, which laid the foundations for the $500 billion digital advertising industry. Perry's reinvention of the Pareto Principle is featured in Harvard Business Review. NASA's Jet Propulsion Labs uses his 80/20 Curve for productivity. He founded the $10 million Evolution 2.0 Prize, announced at London's Royal Society, the world's largest science research challenge. Perry is a co-founder of the AACR's Cancer & Evolution Working Group. Based in Chicago with his family, Perry's influence extends across over 300 industries.Listen to this informative Sharkpreneur episode with Perry Marshall about the 80/20 sales and marketing revolution.Here are some of the beneficial topics covered on this week's show:- How the 80/20 rule is a universal principle applicable beyond business.- Why you shouldn't rely on quick-fix tactics that eventually become obsolete.- How asking deeper questions and pursuing curiosity unlocks new insights. - Why the best scientists maintain their curiosity and humanity.- How meaningful connections and insights can emerge from following your passions.Connect with Perry:Guest Contact InfoX: @PerryMarshallFacebook: facebook.com/perrymarshallcomLinks Mentioned: https://www.perrymarshall.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Perry Marshall is a world-renowned business strategist, celebrated for his expertise in applying the 80/20 Principle to transform businesses from seven-figure revenue to eight figures. Endorsed by FORBES and INC Magazine, Perry is one of the most expensive and influential consultants. He has authored ten books, including the acclaimed Ultimate Guide to Google Ads, which laid the foundations for the $500 billion digital advertising industry. Perry's reinvention of the Pareto Principle is featured in Harvard Business Review. NASA's Jet Propulsion Labs uses his 80/20 Curve for productivity. He founded the $10 million Evolution 2.0 Prize, announced at London's Royal Society, the world's largest science research challenge. Perry is a co-founder of the AACR's Cancer & Evolution Working Group. Based in Chicago with his family, Perry's influence extends across over 300 industries. Listen to this informative Sharkpreneur episode with Perry Marshall about the 80/20 sales and marketing revolution. Here are some of the beneficial topics covered on this week's show: - How the 80/20 rule is a universal principle applicable beyond business. - Why you shouldn't rely on quick-fix tactics that eventually become obsolete. - How asking deeper questions and pursuing curiosity unlocks new insights. - Why the best scientists maintain their curiosity and humanity. - How meaningful connections and insights can emerge from following your passions. Connect with Perry: Guest Contact Info X: @PerryMarshall Facebook: facebook.com/perrymarshallcom Links Mentioned: https://www.perrymarshall.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-396 Overview: Listen in as we discuss the health risks of e-cigarette use and dual use, emphasizing the importance of primary prevention and supporting patients in their cessation efforts. Discover the latest evidence on vaping's impact on addiction, cardiovascular health, and lung cancer, and gain essential insights to better advise your patients. Episode resource links: Bittoni MA, et al. Abstract 2213. Presented at: American Association for Cancer Research Annual Meeting; April 5-10, 2024; San Diego. (AACR 2024: Ohio State experts share new findings at annual meeting (press release). Available at: https://cancer.osu.edu/news/aacr-2024-ohio-state-experts-share-new-findings. Posted April 5,2024. Accessed May 3, 2024.) Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. Apr 29 2021;4:CD010216. doi:10.1002/14651858.CD010216.pub5 Hopkinson NS, et al "Association of time spent on social media with youth cigarette smoking and e-cigarette use in the UK: a national longitudinal study" Thorax 2024: DOI:10.1136/ thorax-2023-220569. Y.W. Kim, E.J. Park, K.I. Kwak, A.-R. Choi, B.J. Lee, Y.J. Lee, J.S. Park, Y.-J. Cho, J.H. Lee, and C.-T. Lee. Association of Electronic Cigarette Use After Conventional Smoking Cessation With Lung Cancer Risk: A Nationwide Cohort Study (abstract). Am J Respir Crit Care Med 2024;209:A3051. CDC: Health Effects of Vaping; https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html CDC:Dual Use of Tobacco Products; https://www.cdc.gov/tobacco/campaign/tips/diseases/dual-tobacco-use.html Guest: Susan Feeney, DNP, FNP-BC, NP-C  Music Credit: Richard Onorato Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-396 Overview: Listen in as we discuss the health risks of e-cigarette use and dual use, emphasizing the importance of primary prevention and supporting patients in their cessation efforts. Discover the latest evidence on vaping's impact on addiction, cardiovascular health, and lung cancer, and gain essential insights to better advise your patients. Episode resource links: Bittoni MA, et al. Abstract 2213. Presented at: American Association for Cancer Research Annual Meeting; April 5-10, 2024; San Diego. (AACR 2024: Ohio State experts share new findings at annual meeting (press release). Available at: https://cancer.osu.edu/news/aacr-2024-ohio-state-experts-share-new-findings. Posted April 5,2024. Accessed May 3, 2024.) Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. Apr 29 2021;4:CD010216. doi:10.1002/14651858.CD010216.pub5 Hopkinson NS, et al "Association of time spent on social media with youth cigarette smoking and e-cigarette use in the UK: a national longitudinal study" Thorax 2024: DOI:10.1136/ thorax-2023-220569. Y.W. Kim, E.J. Park, K.I. Kwak, A.-R. Choi, B.J. Lee, Y.J. Lee, J.S. Park, Y.-J. Cho, J.H. Lee, and C.-T. Lee. Association of Electronic Cigarette Use After Conventional Smoking Cessation With Lung Cancer Risk: A Nationwide Cohort Study (abstract). Am J Respir Crit Care Med 2024;209:A3051. CDC: Health Effects of Vaping; https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html CDC:Dual Use of Tobacco Products; https://www.cdc.gov/tobacco/campaign/tips/diseases/dual-tobacco-use.html Guest: Susan Feeney, DNP, FNP-BC, NP-C  Music Credit: Richard Onorato Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Elizabeth Jaffee, MD, is an internationally recognized expert in cancer immunology and pancreatic cancer. She is the Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Co-director of the Skip Viragh Center for Pancreatic Cancer and Associate Director of the Bloomberg Kimmel Institute for Cancer Immunotherapy. Her research focuses on developing novel immunotherapies for the treatment and prevention of pancreatic cancer. Dr. Jaffee is a past president of AACR. She has served on a number of committees at the National Cancer Institute including the Co-chair of the Biden Moonshot Blue Ribbon Panel which identified high research priorities for the NCI. “You can be an amazing scientist, but what's most important is that whatever you do in science has implications for the patient.” From being inspired by Dr. Marie Curie's biography as a child to now becoming one of the leading names in pancreatic cancer research internationally, Dr. Elizabeth Jaffee helps us re-focus on the patient and our role as ‘physician' scientists. Tune in to this episode of The Medicine Mentors as we journey with Dr. Jaffee to connect the science with the patient. Pearls of Wisdom:   1. Regardless of the direction we take in our professional journey, we have to keep the implications of our actions and research focused on our patients and how we can help them. 2. While leadership is a forefront activity and mentorship an educational activity, both can be thought of as similar in that you're helping someone become the best version of themselves. That means taking into account each individual's strengths and weaknesses and tailoring that to the intended outcome. 3. Don't have just one mentor. It's futile hoping that one person can teach you everything you'll need to know. Find a network of individuals that can help you, which starts by putting yourself out there as someone who wants to do more and wants help.  

Dr. Hahn is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard. He serves as an Executive Vice President and the Chief Operating Officer at the Dana-Farber Cancer Institute. Dr. Hahn has made numerous discoveries that have informed our currentmolecular understanding of cancer. His laboratory has pioneered the use of integrated functional genomic approaches to identify and validate cancer targets. The tools, models and approaches that his laboratory has developed are widely used worldwide to discover and validate molecularly targeted cancer therapies. Dr. Hahn has served as the President of the American Society for ClinicalInvestigation and has been elected to the Association of American Physicians and the National Academy of Medicine. Dr. Hahn has been the recipient of many honors and awards including the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer (2000), a Howard Temin Award from the National Cancer Institute (2001), the Ho-Am Prize in Medicine (2010), the Richard and Hinda Rosenthal Award from AACR (2015) and the Claire and Richard Morse Award (2019). He has been elected to the American Society of Clinical Investigation, American Association of Physicians, the National Academy of Inventors and the National Academy of Medicine.

We've seen tremendous progress in diagnosing and treating cancer, but not all people have benefited from that progress equally. The American Association for Cancer Research recently released their 2024 Cancer Disparities Progress Report, which highlights gaps in diagnoses, treatment, and outcomes for people in marginalized groups. What is being done to close those gaps? We talk with Mitch Stoller, Chief Philanthropic Officer and Vice President of Development for the AACR, and Dr. Camille Ragin, a professor and Associate Director of Diversity, Equity, and Inclusion at Fox Chase Cancer Center and a member of the steering committee for the AACR's report. And on Shara in the City, we get ready for the first year of Olympic breakdancing by visiting Philly's longest-running hip-hop and breakdancing event, The Gathering at The Rotunda. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In this weeks episode, we will have the part two of Dr Barrie Tan's episode. The information you will learn from todays episode - if you take it onboard, will indeed change your life, longevity and health for the better so this is a must listen to podcast with actionable insights and incredible clinical research behind it. What you will learn:  Who is Dr. Barrie Tan?. What is Vitamin E - Tocotrienol? What is GG? What is the difference between tocotrienol and GG?  What is the difference between tocotrienol and tocopherol? Which annatto should you take? What is the link between CoQ10 and statins and GG. What is the link between GG and testosterone? Why should you take MK-4 and GG?... Tocotrienols roles in bone density Tocotrienols roles in Non alcoholic fatty liver disease, pre diabetes, diabetes, cardiovascular disease Tocotrienols role in fighting various cancer types GG's role in bone density, muscle synthesis, coenzyme Q10 absorption and much much more. website  https://barrietan.com/ Riverside Nutrition his manufacturing company - The research mentioned in this show is available at https://americanrivernutrition.com/ If you want to get GG, Tocotrienols or Coqnol (Coenzyme Q10 with GG), you can reach us out directly through our email support@lisatamati.com and we can organize that. BIO A scientist first and foremost, Dr. Tan earned his Ph.D. in chemistry/biochemistry from the University of Otago, New Zealand, and spent several years as a professor at UMass. Dr. Tan has committed himself to the research and development of phytonutrients — natural compounds found in plants that reduce and slow chronic disorders. Dr. Barrie Tan is hailed as a trailblazer and the world's foremost expert on vitamin E, credited with discovering tocotrienol in three major natural sources and geranylgeraniol, an essential nutrient with implications for sports and active nutrition. A scientist first and foremost, Dr. Tan earned his Ph.D. in Chemistry/Biochemistry from the University of Otago, New Zealand and spent several years as a professor at UMass. Today, his research focuses on lipid-soluble nutrients that reduce and slow chronic conditions. Dr. Tan is credited with discovering a form of vitamin E called tocotrienol from three major sources: palm, rice, and annatto — a natural dye and food coloring derived from the seeds of the achiote tree, known for its potential health benefits, including antioxidant and antimicrobial properties. Editor of two prestigious books on tocotrienol and founder of the International Tocotrienol Conference, Dr. Tan was dubbed the "Tocotrienol King" by Dr. Stephen Sinatra, a highly respected and sought-after cardiologist. Dr. Tan has held roles of Chief Scientific Officer and Scientific Board Member for multinational organizations. His career includes periods working in association with the US Armed Forces and a Prince of Thailand. He has successfully launched multiple businesses in the nutrition industry and owns an array of patents and intellectual property, keeping him at the forefront of scientific innovation. He is an internationally celebrated and sought-after speaker, having presented at multiple respected conferences in the field including; IFT, ADA, ASN, IHS, A4M, NPA, AACR, ICIM, IAOMT, and the Academy of Nutrition and Dietetics. Dr. Tan is currently the President of American River Nutrition, a natural health R&D company he started with his wife, Elizabeth, in 1998. Described as a scientific pioneer, his mission is simple: improve the everyday health of people's lives through the rigorous application of DeltaGold® – the first-ever tocopherol-free tocotrienol product extracted from annatto, and the most potent form of vitamin E in existence today. As for links, we'd love to give people a free copy of his eBook The Truth About Vitamin E which can be found at https://barrietan.com/book/ using code: Pushing The Limits   Personalised Health Optimisation Consulting with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clinician with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. She can assist with all functional medicine testing. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis Heavy Metals  Nutristat Omega 3 to 6 status and more  Lisa and her functional medicine colleagues in the practice can help you navigate the confusing world of health and medicine . She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whatever the  challenge you are facing from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out to hormone optimisation to the latest in longevity science. Book your consultation with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community Or if you just want to support Lisa with a "coffee" go to  https://www.buymeacoffee.com/LisaT to donate $3   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialized range of exclusive longevity, health optimizing supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her family but couldn't get in NZ that's what it's in her range. Lisa is constantly researching and interviewing the top scientists and researchers in the world to get you the best cutting edge supplements to optimize your life.   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books Lisa has published 5 books: Running Hot, Running to Extremes, Relentless, What your oncologist isn't telling you and her latest "Thriving on the Edge"  Check them all out at  https://shop.lisatamati.com/collections/books   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr Minkoff here:    Use code "tamati" at checkout to get a 10% discount on any of their devices.   Red Light Therapy: Lisa is a huge fan of Red Light Therapy and runs a Hyperbaric and Red Light Therapy clinic. If you are wanting to get the best products try Flexbeam: A wearable Red Light Device https://recharge.health/product/flexbeam-aff/?ref=A9svb6YLz79r38   Or Try Vielights' advanced Photobiomodulation Devices Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com and use code “tamati” to get 10% off     Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts.  To pushing the limits, Lisa and team

In this weeks episode, world renown Vitamin E researcher and also GG researcher, author and founder of American River Nutrition is today's illustrious guest, Dr Barrie Tan. The information you will learn from todays episode - if you take it onboard, will indeed change your life, longevity and health for the better so this is a must listen to podcast with actionable insights and incredible clinical research behind it. What you will learn:  Who is Dr. Barrie Tan?. What is Vitamin E - Tocotrienol? What is GG? What is the difference between tocotrienol and GG?  What is the difference between tocotrienol and tocopherol? Which annatto should you take? What is the link between CoQ10 and statins and GG. What is the link between GG and testosterone? Why should you take MK-4 and GG?... Tocotrienols roles in bone density Tocotrienols roles in Non alcoholic fatty liver disease, pre diabetes, diabetes, cardiovascular disease Tocotrienols role in fighting various cancer types GG's role in bone density, muscle synthesis, coenzyme Q10 absorption and much much more. website  https://barrietan.com/ Riverside Nutrition his manufacturing company - The research mentioned in this show is available at https://americanrivernutrition.com/ If you want to get GG, Tocotrienols or Coqnol (Coenzyme Q10 with GG), you can reach us out directly through our email support@lisatamati.com and we can organize that. BIO A scientist first and foremost, Dr. Tan earned his Ph.D. in chemistry/biochemistry from the University of Otago, New Zealand, and spent several years as a professor at UMass. Dr. Tan has committed himself to the research and development of phytonutrients — natural compounds found in plants that reduce and slow chronic disorders. Dr. Barrie Tan is hailed as a trailblazer and the world's foremost expert on vitamin E, credited with discovering tocotrienol in three major natural sources and geranylgeraniol, an essential nutrient with implications for sports and active nutrition. A scientist first and foremost, Dr. Tan earned his Ph.D. in Chemistry/Biochemistry from the University of Otago, New Zealand and spent several years as a professor at UMass. Today, his research focuses on lipid-soluble nutrients that reduce and slow chronic conditions. Dr. Tan is credited with discovering a form of vitamin E called tocotrienol from three major sources: palm, rice, and annatto — a natural dye and food coloring derived from the seeds of the achiote tree, known for its potential health benefits, including antioxidant and antimicrobial properties. Editor of two prestigious books on tocotrienol and founder of the International Tocotrienol Conference, Dr. Tan was dubbed the "Tocotrienol King" by Dr. Stephen Sinatra, a highly respected and sought-after cardiologist. Dr. Tan has held roles of Chief Scientific Officer and Scientific Board Member for multinational organizations. His career includes periods working in association with the US Armed Forces and a Prince of Thailand. He has successfully launched multiple businesses in the nutrition industry and owns an array of patents and intellectual property, keeping him at the forefront of scientific innovation. He is an internationally celebrated and sought-after speaker, having presented at multiple respected conferences in the field including; IFT, ADA, ASN, IHS, A4M, NPA, AACR, ICIM, IAOMT, and the Academy of Nutrition and Dietetics. Dr. Tan is currently the President of American River Nutrition, a natural health R&D company he started with his wife, Elizabeth, in 1998. Described as a scientific pioneer, his mission is simple: improve the everyday health of people's lives through the rigorous application of DeltaGold® – the first-ever tocopherol-free tocotrienol product extracted from annatto, and the most potent form of vitamin E in existence today. As for links, we'd love to give people a free copy of his eBook The Truth About Vitamin E which can be found at https://barrietan.com/book/ using code: Pushing The Limits   Personalised Health Optimisation Consulting with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clinician with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. She can assist with all functional medicine testing. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis Heavy Metals  Nutristat Omega 3 to 6 status and more  Lisa and her functional medicine colleagues in the practice can help you navigate the confusing world of health and medicine . She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whatever the  challenge you are facing from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out to hormone optimisation to the latest in longevity science. Book your consultation with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community Or if you just want to support Lisa with a "coffee" go to  https://www.buymeacoffee.com/LisaT to donate $3   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialized range of exclusive longevity, health optimizing supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her family but couldn't get in NZ that's what it's in her range. Lisa is constantly researching and interviewing the top scientists and researchers in the world to get you the best cutting edge supplements to optimize your life.   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books Lisa has published 5 books: Running Hot, Running to Extremes, Relentless, What your oncologist isn't telling you and her latest "Thriving on the Edge"  Check them all out at  https://shop.lisatamati.com/collections/books   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr Minkoff here:    Use code "tamati" at checkout to get a 10% discount on any of their devices.   Red Light Therapy: Lisa is a huge fan of Red Light Therapy and runs a Hyperbaric and Red Light Therapy clinic. If you are wanting to get the best products try Flexbeam: A wearable Red Light Device https://recharge.health/product/flexbeam-aff/?ref=A9svb6YLz79r38   Or Try Vielights' advanced Photobiomodulation Devices Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com and use code “tamati” to get 10% off     Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts.  To pushing the limits, Lisa and team

In today's episode of Beating Cancer Daily, Saranne takes us on an exhilarating journey to the annual AACR convention, a gathering of the world's leading oncological researchers committed to eradicating cancer. As a Stage IV cancer conqueror with no visible disease, she highlights the cutting-edge advancements and personal triumphs reverberating through the halls of this inspiring event. Saranne's perspective as a survivor, researcher, and patient advocate shines a light on how vital patient input is in the search for the next big breakthrough. Dive in as she discusses how anyone touched by cancer can leverage the AACR resources to become more involved, from learning about the latest research to supporting clinical trials. Let's harness the shared hope and collective effort to beat cancer daily.The #1 Rated Cancer Survivor Podcast by FeedSpot and Ranked Top 5 Best Cancer Podcast by CancerCare News. Beating Cancer Daily is listened to in over 77 countries on 6 continents and has over 260 daily episodes!  In 1999, Saranne launched The ComedyCures Foundation from her chemo chair with a "Chemo Comedy Party." Now cancer-free, she's dedicated her life to helping others find strength, courage, and laughter in their fight against cancer. As a healthcare thought leader, speaker, patient advocate, and health and happiness expert, Saranne's work has garnered recognition and support from prestigious organizations like the NIH/NCI, the United Nations, the World Health Organization, and numerous universities and cancer societies. Saranne's transformative strategies, research findings, fun, practical tips, and comic insights can be found in the "Beating Cancer Daily" podcast and the BCD Membership Circle, where she helps listeners navigate their treatment and survivorship with humor and resilience. Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org?By becoming a supporter of ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide. Choose your level of support:• Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annually Donate Herehttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJT We Share the Laughter with Beating Cancer Daily Podcast Do you love the podcast? Please share it with a friend and spread the laughter!  

Join Scrip's China-based editors Brian Yang and Dexter Yan in this Chinese/English podcast as they look at data presented to AACR by Chinese pharma firms and recent acquisitions of China-based companies. UK-based writer Andrew McConaghie also joins to provide his perspectives, including on the proposed US BIOSECURE Act. https://scrip.citeline.com/SC150164/China-Biotech-Podcast-AACR-BIOSECURE-European-Perspectives

Beating Cancer Daily is the #1 ranked Cancer Survivor Podcast in 2024, helping listeners daily in 73 countries with over 250+ episodes. Today is super fun because Saranne invites you to her unique “Pajama Party” guest episode! Join Saranne and award-winning NBC correspondent, cancer survivor, and cancer advocate Kristen Dahlgren in their hotel room at the American Association of Cancer Research (AACR) Conference. And yes, they really are talking to you in their pajamas as they spontaneously share Saranne's podcast microphone (on Saranne's bed) to let you in behind the scenes in San Diego at this massive international cancer conference with 22,000 cancer researchers and cancer experts. (See their Beating Cancer Daily pajama podcast episode photo @ComedyCures.)Learn why Kristen, a medical reporter for NBC, The Today Show, and The Nightly News for more than two decades, traded in her journalism credentials live on the air, just weeks ago, for a role on the frontlines of cancer advocacy.Laugh with these two cancer survivors as they share why “This is the most hopeful time in cancer research.”Dive deeper into why Kristen and Saranne are collaborating with the top scientists to accelerate cancer vaccine discoveries. You will uncover why you should care and then hopefully join their research movement. You can even win your very own “Cancer Research Pajama Party”!This is more than an episode; it's an invitation to be part of history with indomitable souls who are turning the fight against cancer into a mission filled with joy, humor, science, and unwavering dedication to others.Upon launching her “Pink Eraser Project,” Kristen was introduced to stage IV survivor Saranne, who has been cancer-free for decades and serving as a global patient advocate. In 1999, Saranne launched The ComedyCures Foundation from her chemo chair with a "Chemo Comedy Party." Saranne has dedicated her life to helping others find strength, courage, empowerment, and laughter in their fight against cancer. As a healthcare thought leader, cancer researcher, speaker, patient advocate, and happiness expert, Saranne's work has garnered recognition and support from prestigious organizations like the NIH/NCI, the United Nations, the World Health Organization, AACR, ACS, Komen, numerous universities, hospitals, and cancer organizations. Saranne's transformative strategies, research findings, fun, practical tips, and comic insights can be found throughout the Beating Cancer Daily podcast, helping listeners to navigate their treatment and survivorship with humor and resilience.Are you wondering How You Can Support Beating Cancer Daily and ComedyCures?Supporting ComedyCures will help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide.Choose your level of support:• Supporter: $60 (or $5 per month)• Friend: $180 (or $15 per month)• Champion: $600 (or $50 per month)• VIP: $5,000 annuallyDonate HereShare the Laughter with Beating Cancer Daily Podcast.Do you love the podcast, or do you have a suggestion? Go to ComedyCures.org and record a message or write a note to Saranne.

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute. At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including: • The study design, which includes triple-class–refractory patients • The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience • The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients • Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections • The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation • And more!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer is planning to bring an RSV shot to adults aged 18-59, while Boehringer Ingelheim is facing staff layoffs due to biosimilar challenges. Amylyx made a rare move by pulling an ALS drug from the market. On the regulatory front, the FDA has approved CAR-T therapies from J&J and Bristol Myers for earlier use in myeloma patients. Sage's depression drugs are facing hurdles, with the first medicine approved for postpartum depression not gaining traction and challenges in launching its second drug. Real-world evidence is becoming increasingly important in comparative effectiveness research, highlighting the need for a new approach to sales team development and coaching in biopharma companies. The industry is experiencing various challenges and advancements that are shaping the future of healthcare.A new study found that GLP-1 receptor agonists like Novo Nordisk's Ozempic do not increase the risk of thyroid cancer. Another study presented at AACR suggests that drugs approved through accelerated approval may not always lead to clinical benefit. Merck and Kelun's anti-Trop2 ADC shows promise in gastric cancer, while Torl Biotherapeutics secures funding for ADC therapies. Less than half of cancer drugs approved via accelerated approval showed clinical benefit in confirmatory trials. There are also job listings and other news updates related to the pharmaceutical industry.The resurgence of a shelved radioactive cancer therapy is making a comeback after being developed abroad for decades. The radiotherapy market is growing, with estimates suggesting it could be valued at $8.8 billion by 2028. Radiotherapy is commonly used in oncology to destroy cancer cells, but it carries risks of damaging surrounding tissue. Precision medicine innovations, such as stereotactic body radiation therapy, are being developed to target tumors more accurately. There is also increasing focus on psychiatric drugs in the pharma industry, as well as challenges and opportunities in the biosimilar market. The text includes information about a survey on what emerging biotechs want from CROs and CDMOs, recent developments in the pharmaceutical industry like job cuts at Novartis and partnerships in cancer drug development, a poll about running clinical trials in Ukraine during the ongoing war, and offers links to resources on patient support hubs, emerging biotechs, and the obesity drug revolution.

M&A has been driving a recovery for biotech, with $62 billion in takeouts in the past six months restocking specialist investors' coffers for their next wave of investments. On the latest BioCentury This Week podcast, BioCentury's editors assess the state of the public markets heading into the second quarter, including the outsize role PIPEs have had in financing industry's comeback. They also discuss their takeaways from analyzing nearly 7,000 abstracts from the American Association for Cancer Research and the editors' insights on why degrader-antibody conjugates are emerging as the next contenders to build on the success of the antibody-drug conjugates paradigm. Editor in Chief Simone Fishburn also previews Grand Rounds, BioCentury's first R&D conference, which will focus on the biotech industry's interface with academia, bringing together decision-makers and the next innovators in Nashville Sept. 9-11. To learn more about BioCentury Grand Rounds and opportunities to present, see the conference website. This week's podcast is sponsored by Jeito Capital. 

In today's episode of Beating Cancer Daily, Saranne takes us on an exhilarating journey to the annual AACR convention, a gathering of the world's leading oncological researchers committed to eradicating cancer. As a Stage IV cancer conqueror with no visible disease, she highlights the cutting-edge advancements and personal triumphs reverberating through the halls of this inspiring event. Saranne's perspective as a survivor, researcher, and patient advocate shines a light on how vital patient input is in the search for the next big breakthrough. Dive in as she discusses how anyone touched by cancer can leverage the AACR resources to become more involved, from learning about the latest research to supporting clinical trials. Let's harness the shared hope and collective effort to beat cancer daily.Meet Saranne Rothberg, Cancer Survivor and Laughter AdvocateIn 1999, Saranne launched The ComedyCures Foundation from her chemo chair with a "Chemo Comedy Party." Now cancer-free, she's dedicated her life to helping others find strength, courage, and laughter in their fight against cancer. As a healthcare thought leader, speaker, patient advocate, and health and happiness expert, Saranne's work has garnered recognition and support from prestigious organizations like the NIH/NCI, the United Nations, the World Health Organization, and numerous universities and cancer societies. Saranne's transformative strategies, research findings, fun, practical tips, and comic insights can be found in the "Beating Cancer Daily" podcast and the BCD Membership Circle, where she helps listeners navigate their treatment and survivorship with humor and resilience.Are you wondering How You Can Support Beating Cancer Daily and ComedyCures.org?By supporting ComedyCures.org, you'll help us continue our essential programs and research. Your generosity will significantly impact cancer patients, caregivers, doctors, nurses, and researchers worldwide.Choose your level of support:• Supporter: $50 (or $5 per month)• Friend: $150 (or $15 per month)• Champion: $500 (or $50 per month)• VIP: $5,000 annuallyhttps://www.paypal.com/donate?hosted_button_id=GDPQCM8PHJTWe Share the Laughter with Beating Cancer Daily Podcast.Do you love the podcast?Please share it with a friend and spread the laughter!

Experiencing muscle discomfort from statins? Curious about natural ways to alleviate these symptoms and boost your heart health? In this episode, explore the role of geranylgeraniol (GG) and coenzyme Q10 (CoQ10) in supporting muscles affected by statins with repeat guest, Dr. Barrie Tan, the world's foremost expert on annatto, geranylgeraniol (GG), vitamin K in the form of MK-4 and vitamin E in the form of tocotrienols. Get ready to discover the benefits of these essential compounds that support cardiovascular health and muscle function, especially in individuals taking statins. A scientist first and foremost, Dr. Tan earned his Ph.D. in chemistry/biochemistry from the University of Otago, New Zealand, and spent several years as a professor at UMass. Dr. Tan has committed himself to the research and development of phytonutrients — natural compounds found in plants that reduce and slow chronic disorders. Dr. Tan is credited with discovering a form of vitamin E called tocotrienol from three major sources: palm, rice, and annatto — a natural dye and food coloring derived from the seeds of the achiote tree, known for its potential health benefits, including antioxidant and antimicrobial properties. Editor of two prestigious books on tocotrienol and founder of the International Tocotrienol Conference, Dr. Tan was dubbed the “Tocotrienol King” by Dr. Stephen Sinatra, a highly respected and sought-after cardiologist. Dr. Tan has held roles of Chief Scientific Officer and Scientific Board Member for multinational organizations. His career includes periods working in association with the US Armed Forces and a Prince of Thailand. He has successfully launched multiple businesses in the nutrition industry and owns an array of patents and intellectual property, keeping him at the forefront of scientific innovation. He is an internationally celebrated and sought-after speaker, having presented at multiple respected conferences in the field including; IFT, ADA, ASN, IHS, A4M, NPA, AACR, ICIM, IAOMT, and the Academy of Nutrition and Dietetics. Dr. Tan is currently the President of American River Nutrition, a natural health R&D company he started with his wife, Elizabeth, in 1998. Described as a scientific pioneer, his mission is simple: improve the everyday health of people's lives through the rigorous application of DeltaGold® – the first-ever tocopherol-free tocotrienol product extracted from annatto, and the most potent form of vitamin E in existence today. Be sure to check out Dr. Tan's formulations for Designs for Health (use code BEN15 to save 15%): For the full show notes, visit: https://bengreenfieldlife.com/ggpodcast Episode Sponsors: Organifi: Go to Organifi.com/Ben for 20% off your order. Ned: Get 15% off Ned products with code GREENFIELD by going to helloned.com/GREENFIELD. Ipothecary: Go to ipothecarystore.com/ben and use code BEN20 for 20% off. Clearlight Sauna: Go to HealwithHeat.com and use code BEN for a discount and free shipping. Limitless Life Nootropics: Visit limitlesslifenootropics.com/bengpeptides and use the code BEN at checkout for an exclusive discount.  See omnystudio.com/listener for privacy information.

BUFFALO, NY- March 11, 2024 – Impact Journals publishes #scholarly journals in the #biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.” Visit booth number 4159 at the AACR Annual Meeting 2024 to connect with members of the Oncotarget team. About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open-access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media at: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In the classic holiday film "It's a Wonderful Life", Clarence the angel says "remember, George, no man is a failure who has friends". In the holiday spirit, Your Doctor Friends took Clarence's words to heart, and present to you today the research behind how friendship keeps us healthy. In today's episode, we highlight the growing amount of evidence that supports friendships as a key aspect of our health, and, conversely, how social and emotional isolation often leads to poor health outcomes. The American Psychological Association summarizes, “given the clear benefits of friendship, psychologists say we should promote platonic social connection across society—including in school, at work, in public spaces (such as on public transportation), and through entertainment.” So let's do that today, shall we? And after listening to the episode, maybe reach out to a friend with a quick text, a silly photo, or an invite to meet up for a treat together. It might just help you live longer ;) And bonus dessert topic at the end, we talk about SOME GOOD NEWS in cancer treatment and survivorship! Happy holidays from Your Doctor Friends! We hope you're safe, happy, and healthy :) Resources for today's episode include: An American Psychological Association article titled "The science of why friendships keep us healthy". A Washington Post article titled "Friends can improve your health and well-being especially during the holidays". A systematic review/meta-analysis in PLoS One from 2023 titled "Social isolation as a risk factor for all-cause mortality" A Healio article titled "Cancer death rate drops by 33%, AACR report shows" The AACR press release for the Cancer Progress Report. The full AACR Cancer Progress Report 2023. For more episodes, limited edition merch, or to become a Friend of Your Doctor Friends (and more), follow this link! This includes the famous "Advice from the last generation of doctors that inhaled lead" shirt :) Also, CHECK OUT AMAZING HEALTH PODCASTS on The Health Podcast Network   Find us at: Website: yourdoctorfriendspodcast.com  Email: yourdoctorfriendspodcast@gmail.com  Connect with us: @your_doctor_friends (IG) Send/DM us a voice memo/question and we might play it on the show! @yourdoctorfriendspodcast1013 (YouTube) @JeremyAllandMD (IG, FB, Twitter) @JuliaBrueneMD (IG) @HealthPodNet (IG)